Phase II/III trial of patients with Pompe disease previously treated with alglucosidase alfa who were then switched to treatment with reveglucosidase alfa

Trial Profile

Phase II/III trial of patients with Pompe disease previously treated with alglucosidase alfa who were then switched to treatment with reveglucosidase alfa

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 01 Mar 2016

At a glance

  • Drugs Reveglucosidase alfa (Primary)
  • Indications Glycogen storage disease type II
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Mar 2016 New trial record
    • 25 Feb 2016 According to BioMarin Pharmaceutical media release, the company shared interim results.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top